5 Undervalued Price-to-Book Stocks Worth Adding to Your Portfolio
Harmony Biosciences, Invesco, GM, HPE and Quanex made the screen of low price-to-book stocks that also met multiple value metrics.
Zacks Investment Research7/28/2026Positive
HRMY
Harmony Biosciences HoldingsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.07B
P/E Ratio
14.54
EPS
$2.46
Beta
0.94
52W High
$40.87
52W Low
$25.52
50-Day MA
$33.97
200-Day MA
$32.91
Dividend Yield
—
Profit Margin
16.20%
Forward P/E
10.88
PEG Ratio
—
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.
Fundamentals
| Revenue (TTM) | $899.11M |
| Gross Profit (TTM) | $688.25M |
| EBITDA | $214.85M |
| Operating Margin | 17.30% |
| Return on Equity | 17.90% |
| Return on Assets | 10.20% |
| Revenue/Share (TTM) | $15.60 |
| Book Value | $15.73 |
| Price-to-Book | 2.29 |
| Price-to-Sales (TTM) | 2.30 |
| EV/Revenue | 1.782 |
| EV/EBITDA | 6.76 |
| Quarterly Earnings Growth (YoY) | -29.50% |
| Quarterly Revenue Growth (YoY) | 16.60% |
| Shares Outstanding | $57.89M |
| Float | $51.73M |
| % Insiders | 11.70% |
| % Institutions | 103.09% |
Historical Volatility
HV 10-Day
64.90%
HV 20-Day
53.46%
HV 30-Day
45.71%
HV 60-Day
41.49%
HV Rank
74.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($45.40 target)
2
Strong Buy4
Buy4
Hold1
Strong SellLatest News
Harmony Biosciences: WAKIX Cash Flow Funds Its Own Disruption
Harmony Biosciences (HRMY) is evolving from a single-product firm into a self-funded neuroscience platform, leveraging robust WAKIX growth. WAKIX posted 30% Q1 revenue growth, supporting a strong balance sheet with $710 million net cash and funding for pipeline expansion. HRMY trades at a deep valuation discount, reflecting market fears of WAKIX cash flow erosion post-2030 and underappreciated pipeline potential.
Seeking Alpha7/28/2026Positive
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences (HRMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research7/28/2026Positive
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Zacks Investment Research7/27/2026Positive
Harmony Biosciences (HRMY) Soars 10.0%: Is Further Upside Left in the Stock?
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks Investment Research7/22/2026Positive
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on August 4, 2026, at 8:30 a.m. ET to discuss the results.
GlobeNewsWire7/21/2026Neutral
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.
Zacks Investment Research7/17/2026Positive
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research7/15/2026Positive
HRMY vs. AMGN: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and Amgen (AMGN). But which of these two companies is the best option for those looking for undervalued stocks?
Zacks Investment Research7/14/2026Positive
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
Five low price-to-book stocks pass our value screens with low P/B, P/S and PEG metrics, highlighting their earnings growth potential.
Zacks Investment Research7/14/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HRMY and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026